{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:35:29Z","timestamp":1790904929646,"version":"4.1.0"},"reference-count":67,"publisher":"The Company of Biologists","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11,1]]},"abstract":"<jats:p>Gaucher disease (GD), the most common lysosomal storage disorder (LSD), is caused by the defective activity of the lysosomal hydrolase glucocerebrosidase, which is encoded by the GBA gene. Generation of animal models that faithfully recapitulate the three clinical subtypes of GD has proved to be more of a challenge than first anticipated. The first mouse to be produced died within hours after birth owing to skin permeability problems, and mice with point mutations in Gba did not display symptoms correlating with human disease and also died soon after birth. Recently, conditional knockout mice that mimic some features of the human disease have become available. Here, we review the contribution of all currently available animal models to examining pathological pathways underlying GD and to testing the efficacy of new treatment modalities, and propose a number of criteria for the generation of more appropriate animal models of GD.<\/jats:p>","DOI":"10.1242\/dmm.008185","type":"journal-article","created":{"date-parts":[[2011,9,28]],"date-time":"2011-09-28T06:30:20Z","timestamp":1317191420000},"page":"746-752","source":"Crossref","is-referenced-by-count":98,"title":["Animal models for Gaucher disease research"],"prefix":"10.1242","volume":"4","author":[{"given":"Tamar","family":"Farfel-Becker","sequence":"first","affiliation":[{"name":"Department of Biological Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einat B.","family":"Vitner","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony H.","family":"Futerman","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"237","reference":[{"key":"2021042500504680700_b1-0040746","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.expneurol.2010.07.023","article-title":"Intracerebroventricular delivery of glucocerebrosidase reduces substrates and increases lifespan in a mouse model of neuronopathic Gaucher disease","volume":"225","author":"Cabrera-Salazar","year":"2010","journal-title":"Exp. Neurol."},{"key":"2021042500504680700_b2-0040746","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10545-010-9095-5","article-title":"The neurological manifestations of Gaucher disease type 1, the French Observatoire on Gaucher disease (FROG)","volume":"33","author":"Cherin","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"2021042500504680700_b3-0040746","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.22400","article-title":"Acid beta-glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter alpha-synuclein processing","volume":"69","author":"Cullen","year":"2011","journal-title":"Ann. Neurol."},{"key":"2021042500504680700_b4-0040746","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/BF02537244","article-title":"Glucosylceramide and the level of the glucosidase-stimulating proteins","volume":"21","author":"Datta","year":"1986","journal-title":"Lipids"},{"key":"2021042500504680700_b5-0040746","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0006-291X(88)80693-4","article-title":"Normalization of liver glucosylceramide levels in the \u201cGaucher\u201d mouse by phosphatidylserine injection","volume":"152","author":"Datta","year":"1988","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021042500504680700_b6-0040746","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0014-5793(99)00274-4","article-title":"Accumulation of protein-bound epidermal glucosylceramides in beta-glucocerebrosidase deficient type 2 Gaucher mice","volume":"447","author":"Doering","year":"1999","journal-title":"FEBS Lett."},{"key":"2021042500504680700_b7-0040746","doi-asserted-by":"crossref","first-page":"13819","DOI":"10.1073\/pnas.0606016103","article-title":"Effective cell and gene therapy in a murine model of Gaucher disease","volume":"103","author":"Enquist","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2021042500504680700_b8-0040746","doi-asserted-by":"crossref","first-page":"17483","DOI":"10.1073\/pnas.0708086104","article-title":"Murine models of acute neuronopathic Gaucher disease","volume":"104","author":"Enquist","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2021042500504680700_b9-0040746","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1634\/stemcells.2008-0844","article-title":"Successful low-risk hematopoietic cell therapy in a mouse model of type 1 Gaucher disease","volume":"27","author":"Enquist","year":"2009","journal-title":"Stem Cells"},{"key":"2021042500504680700_b10-0040746","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/hmg\/ddp061","article-title":"No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease","volume":"18","author":"Farfel-Becker","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"2021042500504680700_b11-0040746","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/hmg\/ddr019","article-title":"Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease","volume":"20","author":"Farfel-Becker","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"2021042500504680700_b12-0040746","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/hmg\/5.6.711","article-title":"Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids","volume":"5","author":"Fujita","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"2021042500504680700_b13-0040746","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/gte.1997.1.5","article-title":"Gaucher disease: gene frequencies and genotype\/phenotype correlations","volume":"1","author":"Grabowski","year":"1997","journal-title":"Genet. Test."},{"key":"2021042500504680700_b14-0040746","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bcmd.2010.08.012","article-title":"Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity","volume":"46","author":"Gupta","year":"2010","journal-title":"Blood Cells Mol. Dis."},{"key":"2021042500504680700_b15-0040746","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/030098587301000302","article-title":"Neurovisceral glucocerebroside storage (Gaucher\u2019s disease) in a dog","volume":"10","author":"Hartley","year":"1973","journal-title":"Vet. Pathol."},{"key":"2021042500504680700_b16-0040746","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1172\/JCI117160","article-title":"Consequences of beta-glucocerebrosidase deficiency in epidermis. Ultrastructure and permeability barrier alterations in Gaucher disease","volume":"93","author":"Holleran","year":"1994","journal-title":"J. Clin. Invest."},{"key":"2021042500504680700_b17-0040746","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10038-004-0155-2","article-title":"Down-regulation of Bcl-2 in the fetal brain of the Gaucher disease mouse model: a possible role in the neuronal loss","volume":"49","author":"Hong","year":"2004","journal-title":"J. Hum. Genet."},{"key":"2021042500504680700_b18-0040746","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3346\/jkms.2006.21.4.733","article-title":"Upregulation of proinflammatory cytokines in the fetal brain of the Gaucher mouse","volume":"21","author":"Hong","year":"2006","journal-title":"J. Korean Med. Sci."},{"key":"2021042500504680700_b19-0040746","first-page":"67","article-title":"Saposin C and other sphingolipid activator proteins","volume-title":"Gaucher Disease","author":"Hoops","year":"2007"},{"key":"2021042500504680700_b20-0040746","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)","volume":"29","author":"Hruska","year":"2008","journal-title":"Hum. Mutat."},{"key":"2021042500504680700_b21-0040746","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcmd.2009.03.006","article-title":"Impaired IL-10 transcription and release in animal models of Gaucher disease macrophages","volume":"43","author":"Kacher","year":"2009","journal-title":"Blood Cells Mol. Dis."},{"key":"2021042500504680700_b22-0040746","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0006-291X(75)90286-7","article-title":"The Gaucher mouse","volume":"67","author":"Kanfer","year":"1975","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021042500504680700_b23-0040746","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10545-010-9230-3","article-title":"Gaucher disease in sheep","volume":"34","author":"Karageorgos","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"2021042500504680700_b24-0040746","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1742-4658.2010.07588.x","article-title":"The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase","volume":"277","author":"Khanna","year":"2010","journal-title":"FEBS J."},{"key":"2021042500504680700_b25-0040746","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/emm.2006.41","article-title":"Downregulation of neurotrophic factors in the brain of a mouse model of Gaucher disease; implications for neuronal loss in Gaucher disease","volume":"38","author":"Kim","year":"2006","journal-title":"Exp. Mol. Med."},{"key":"2021042500504680700_b26-0040746","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1073\/pnas.95.5.2503","article-title":"Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure","volume":"95","author":"Liu","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2021042500504680700_b27-0040746","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.neuro.2009.06.009","article-title":"Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism","volume":"30","author":"Manning-Bog","year":"2009","journal-title":"Neurotoxicology"},{"key":"2021042500504680700_b28-0040746","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1006\/mthe.2002.0650","article-title":"Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model","volume":"6","author":"Marshall","year":"2002","journal-title":"Mol. Ther."},{"key":"2021042500504680700_b29-0040746","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10545-010-9072-z","article-title":"Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy","volume":"33","author":"Marshall","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"2021042500504680700_b30-0040746","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"2021042500504680700_b31-0040746","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/jgm.901","article-title":"AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease","volume":"8","author":"McEachern","year":"2006","journal-title":"J. Gene Med."},{"key":"2021042500504680700_b32-0040746","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","article-title":"A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease","volume":"91","author":"McEachern","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"2021042500504680700_b33-0040746","first-page":"155","article-title":"Type 1 Gaucher disease \u2013 clinical features","volume-title":"Gaucher Disease","author":"Mistry","year":"2007"},{"key":"2021042500504680700_b34-0040746","doi-asserted-by":"crossref","first-page":"19473","DOI":"10.1073\/pnas.1003308107","article-title":"Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage","volume":"107","author":"Mistry","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2021042500504680700_b35-0040746","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1172\/JCI0214530","article-title":"Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage","volume":"109","author":"Mizukami","year":"2002","journal-title":"J. Clin. Invest."},{"key":"2021042500504680700_b36-0040746","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1371\/journal.pbio.0060026","article-title":"Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis","volume":"6","author":"Mu","year":"2008","journal-title":"PLoS Biol."},{"key":"2021042500504680700_b37-0040746","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1073\/pnas.86.13.5049","article-title":"Comparison of the chromosomal localization of murine and human glucocerebrosidase genes and of the deduced amino acid sequences","volume":"86","author":"O\u2019Neill","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2021042500504680700_b38-0040746","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ymgme.2008.12.008","article-title":"Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells","volume":"96","author":"Rigat","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"2021042500504680700_b39-0040746","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1073\/pnas.1108197108","article-title":"CNS expression of glucocerebrosidase corrects {alpha}-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy","volume":"108","author":"Sardi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2021042500504680700_b40-0040746","first-page":"175","article-title":"Neuronopathic Gaucher disease","volume-title":"Gaucher Disease","author":"Schiffmann","year":"2007"},{"key":"2021042500504680700_b41-0040746","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/mds.23774","article-title":"Lysosomal storage disorders and Parkinson\u2019s disease: beyond Gaucher disease","volume":"26","author":"Shachar","year":"2011","journal-title":"Mov. Disord."},{"key":"2021042500504680700_b42-0040746","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","article-title":"Gaucher disease: complexity in a \u201csimple\u201d disorder","volume":"83","author":"Sidransky","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"2021042500504680700_b43-0040746","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1203\/00006450-199210000-00023","article-title":"Gaucher disease in the neonate: a distinct Gaucher phenotype is analogous to a mouse model created by targeted disruption of the glucocerebrosidase gene","volume":"32","author":"Sidransky","year":"1992","journal-title":"Pediatr. Res."},{"key":"2021042500504680700_b44-0040746","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"2021042500504680700_b45-0040746","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2006.09.008","article-title":"Generation of a conditional knockout of murine glucocerebrosidase: utility for the study of Gaucher disease","volume":"90","author":"Sinclair","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"2021042500504680700_b46-0040746","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1471-4159.1978.tb12395.x","article-title":"The Gaucher mouse: differential action of conduritol B epoxide and reversibility of its effects","volume":"30","author":"Stephens","year":"1978","journal-title":"J. Neurochem."},{"key":"2021042500504680700_b47-0040746","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4161\/auto.6.5.12047","article-title":"Impaired autophagosomes and lysosomes in neuronopathic Gaucher disease","volume":"6","author":"Sun","year":"2010","journal-title":"Autophagy"},{"key":"2021042500504680700_b48-0040746","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1096-7192(02)00114-2","article-title":"Prosaposin: threshold rescue and analysis of the \u201cneuritogenic\u201d region in transgenic mice","volume":"76","author":"Sun","year":"2002","journal-title":"Mol. Genet. Metab."},{"key":"2021042500504680700_b49-0040746","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1194\/jlr.M500202-JLR200","article-title":"Gaucher disease mouse models: point mutations at the acid beta-glucosidase locus combined with low-level prosaposin expression lead to disease variants","volume":"46","author":"Sun","year":"2005","journal-title":"J. Lipid Res."},{"key":"2021042500504680700_b50-0040746","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1194\/jlr.M600239-JLR200","article-title":"Conditional expression of human acid beta-glucosidase improves the visceral phenotype in a Gaucher disease mouse model","volume":"47","author":"Sun","year":"2006","journal-title":"J. Lipid Res."},{"key":"2021042500504680700_b51-0040746","doi-asserted-by":"crossref","first-page":"e7320","DOI":"10.1371\/journal.pone.0007320","article-title":"In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse models","volume":"4","author":"Sun","year":"2009","journal-title":"PLoS ONE"},{"key":"2021042500504680700_b52-0040746","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/hmg\/ddp531","article-title":"Specific saposin C deficiency: CNS impairment and acid beta-glucosidase effects in the mouse","volume":"19","author":"Sun","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"2021042500504680700_b53-0040746","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/hmg\/ddp580","article-title":"Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits","volume":"19","author":"Sun","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"2021042500504680700_b54-0040746","doi-asserted-by":"crossref","first-page":"e19037","DOI":"10.1371\/journal.pone.0019037","article-title":"Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse","volume":"6","author":"Sun","year":"2011","journal-title":"PLoS ONE"},{"key":"2021042500504680700_b55-0040746","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/357407a0","article-title":"Animal model of Gaucher\u2019s disease from targeted disruption of the mouse glucocerebrosidase gene","volume":"357","author":"Tybulewicz","year":"1992","journal-title":"Nature"},{"key":"2021042500504680700_b56-0040746","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/icb.1979.56","article-title":"Canine Gaucher disease-the enzymic defect","volume":"57","author":"Van De Water","year":"1979","journal-title":"Aust. J. Exp. Biol. Med. Sci."},{"key":"2021042500504680700_b57-0040746","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s10545-009-1164-2","article-title":"Management of neuronopathic Gaucher disease: revised recommendations","volume":"32","author":"Vellodi","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"2021042500504680700_b58-0040746","doi-asserted-by":"crossref","first-page":"20423","DOI":"10.1074\/jbc.R110.134452","article-title":"Common and uncommon pathogenic cascades in lysosomal storage diseases","volume":"285","author":"Vitner","year":"2010","journal-title":"J. Biol. Chem."},{"key":"2021042500504680700_b59-0040746","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1093\/hmg\/ddq273","article-title":"Altered expression and distribution of cathepsins in neuronopathic forms of Gaucher disease and in other sphingolipidoses","volume":"19","author":"Vitner","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"2021042500504680700_b60-0040746","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF02962142","article-title":"A biochemical and ultrastructural evaluation of the type 2 Gaucher mouse","volume":"24","author":"Willemsen","year":"1995","journal-title":"Mol. Chem. Neuropathol."},{"key":"2021042500504680700_b61-0040746","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ymgme.2004.04.011","article-title":"Neuropathology provides clues to the pathophysiology of Gaucher disease","volume":"82","author":"Wong","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"2021042500504680700_b62-0040746","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0002-9440(10)63566-3","article-title":"Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease","volume":"163","author":"Xu","year":"2003","journal-title":"Am. J. Pathol."},{"key":"2021042500504680700_b63-0040746","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2008.01.013","article-title":"Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels","volume":"94","author":"Xu","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"2021042500504680700_b64-0040746","doi-asserted-by":"crossref","first-page":"e10750","DOI":"10.1371\/journal.pone.0010750","article-title":"Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model","volume":"5","author":"Xu","year":"2010","journal-title":"PLoS ONE"},{"key":"2021042500504680700_b65-0040746","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ymgme.2010.12.014","article-title":"Accumulation and distribution of alpha-synuclein and ubiquitin in the CNS of Gaucher disease mouse models","volume":"102","author":"Xu","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"2021042500504680700_b66-0040746","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2164-12-20","article-title":"Global gene expression profile progression in Gaucher disease mouse models","volume":"12","author":"Xu","year":"2011","journal-title":"BMC Genomics"},{"key":"2021042500504680700_b67-0040746","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/jnr.22371","article-title":"A mutation in the saposin C domain of the sphingolipid activator protein (Prosaposin) gene causes neurodegenerative disease in mice","volume":"88","author":"Yoneshige","year":"2010","journal-title":"J. Neurosci. Res."}],"container-title":["Disease Models &amp; Mechanisms"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.biologists.com\/dmm\/article-pdf\/4\/6\/746\/1580304\/746.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/journals.biologists.com\/dmm\/article-pdf\/4\/6\/746\/1580304\/746.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T00:51:31Z","timestamp":1619311891000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.biologists.com\/dmm\/article\/4\/6\/746\/3140\/Animal-models-for-Gaucher-disease-research"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,1]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,11,1]]}},"URL":"https:\/\/doi.org\/10.1242\/dmm.008185","relation":{},"ISSN":["1754-8411","1754-8403"],"issn-type":[{"value":"1754-8411","type":"electronic"},{"value":"1754-8403","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11,1]]}}}